Currently, the universal blood biomarker used for the risk assessment and surveillance of HCC is serum α-fetoprotein (AFP), but nearly 30% of HCC patients have a normal serum level of AFP (AFP < 25 ng/mL) [4–7]. Here, AFP is linked to hepatocellular carcinoma.